NeoVista, a Fremont ophthalmic device company focusing on the treatment of wet age-related macular degeneration, said it has raised a third $41 million round of venture financing.

The company is in the early stages of testing its technology, and it won’t hit the market until around 2010 at the earliest. Separately, VentureWire reports a comment from the company’s VP of marketing that the company had received interest from a company about a possible acquisition.

New investors Essex Woodlands Health Ventures, which led the current round of financing, and MPM Capital, join existing investors Versant Ventures, SV Life Sciences, the Carlyle Group, and Accuitive Medical Ventures.

NeoVista is developing an intraocular radiation device that shows promising early results in the treatment of so-called “Wet AMD,” which causes deterioration in eye vision.